Axisresearch
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Countries
ANALGESICS MARKET: GLOBAL INDUSTRY TRENDS, SHARE, SIZE, GROWTH, OPPORTUNITY AND FORECAST 2019-2024
| Healthcare | Published by: IMARC GROUP | Market: |
| 102 pages | Published: 02-11-2019 |
- Healthcare
- IMARC GROUP
- 102 pages
- Published: 02-11-2019
The global analgesics market was worth US$ 44.3 Billion in 2018. Pain currently represents a major global health challenge. Worldwide, it has been estimated that 1 out of every 5 adults suffers from pain and that another 1 in in every 10 adults are diagnosed with chronic pain each year. Analgesics (also known as painkillers or pain relievers) are drugs that are taken to relieve pain. They may be taken to relieve pain that arises from a wide range of conditions, such as appendicitis, surgery, infection, headaches, mensuration, cancer, pain syndromes, sprains, strains, toothache, etc. The two major categories of analgesics that are used to treat pain include Opioids and NSAIDs. Majority of the analgesics are taken orally. They may, however, also be taken through other delivery routes such as parenteral, topical, transdermal, rectal, etc.
The global analgesics market is expected to exhibit moderate growth over the next five years. A major factor catalyzing this demand is the strong growth in the geriatric population. In 2017, between 950 Million-1000 Million people were over the age of 60. We expect these numbers to reach 2100 Million by 2050 accounting for 21% of the total global population. The rising older population is expected to increase the incidence of pain arising from a number of chronic and lifestyle diseases. The market for analgesics is also expected to be catalyzed by a strong drug pipeline and high unmet needs. We expect a number of new drugs to be launched in the coming years. Other major factors catalyzing the analgesics market include changing lifestyles, rising prevalence of obesity and overweight, rising prevalence of chronic diseases, etc. Looking forward, the global analgesics market is expected to reach a revenue of US$ 56.8 Billion by 2024, exhibiting a CAGR of around 4% during 2019-2024.
Market Summary:
Based on the drug type, the market has been segmented into prescription analgesics and OTC analgesics. Prescription analgesics currently dominate the market, holding the largest share.
Based on the drug class, the market has been segmented into opioids, NSAIDs and others. Opioids currently represents the biggest segment.
Based on the route of administration, the market has been segmented into oral, parenteral, topical, transdermal and rectal. Currently, oral dominates the market, holding the largest share.
Based on the pain type, the market has been segmented into musculoskeletal pain, surgical and trauma pain, cancer pain, neuropathic pain, migraine, obstetrical pain, fibromyalgia, pain due to burns, dental/facial pain, paediatric pain and others. Musculoskeletal pain currently represents the biggest segment.
Based on the application, the market has been segmented into internal analgesics and external analgesics. Internal analgesics currently represent the biggest segment.
Region-wise, the market has been segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. North America currently represents the biggest market.
The competitive landscape of the market has also been examined with some of the key players being Bayer AG, Novartis AG, GlaxoSmithKline PLC, Pfizer Inc., Johnson & Johnson, Reckitt Benckiser (RB), Endo Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, Sanofi, etc.
Key Questions Answered in This Report:
- How has the global analgesics market performed so far and how will it perform in the coming years?
- What are the key regional markets in the global analgesics industry?
- What is the breakup of the global analgesics market on the basis of drug type?
- What is the breakup of the global analgesics market on the basis of drug class?
- What is the breakup of the global analgesics market on the basis of route of administration?
- What is the breakup of the global analgesics market on the basis of pain type?
- What is the breakup of the global analgesics market on the basis of application?
- What are the various stages in the value chain of the global analgesics market?
- What are the key driving factors and challenges in the global analgesics market?
- What is the structure of the global analgesics market and who are the key players?
- What is the degree of competition in the global analgesics market?
| 1. Preface 2. Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3. Executive Summary 4. Introduction 4.1 Overview 4.2 Properties 4.3 Key Industry Trends 5. Global Analgesics Market 5.1 Market Overview 5.2 Market Performance 5.3 Market Breakup by Type 5.4 Market Breakup by Drug Class 5.5 Market Breakup by ROA 5.6 Market Breakup by Pain Type 5.7 Market Breakup by Application 5.8 Market Breakup by Region 5.9 Market Forecast 6. Market Breakup by Type 6.1 Prescription Analgesics 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 OTC Analgesics 6.2.1 Market Trends 6.2.2 Market Forecast 7. Market Breakup by Drug Class 7.1 Opioids 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 NSAID 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Others 7.3.1 Market Trends 7.3.2 Market Forecast 8. Market Breakup by ROA 8.1 Oral 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Parenteral 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Topical 8.3.1 Market Trends 8.3.2 Market Forecast 8.4 Transdermal 8.4.1 Market Trends 8.4.2 Market Forecast 8.5 Rectal 8.5.1 Market Trends 8.5.2 Market Forecast 9. Market Breakup by Pain Type 9.1 Musculoskeletal Pain 9.1.1 Market Trends 9.1.2 Market Forecast 9.2 Surgical and Trauma Pain 9.2.1 Market Trends 9.2.2 Market Forecast 9.3 Cancer Pain 9.3.1 Market Trends 9.3.2 Market Forecast 9.4 Neuropathic Pain 9.4.1 Market Trends 9.4.2 Market Forecast 9.5 Migraine 9.5.1 Market Trends 9.5.2 Market Forecast 9.6 Obstetrical Pain 9.6.1 Market Trends 9.6.2 Market Forecast 9.7 Fibromyalgia 9.7.1 Market Trends 9.7.2 Market Forecast 9.8 Pain due to Burns 9.8.1 Market Trends 9.8.2 Market Forecast 9.9 Dental/Facial Pain 9.9.1 Market Trends 9.9.2 Market Forecast 9.10 Pediatric Pain 9.10.1 Market Trends 9.10.2 Market Forecast 9.11 Others 9.11.1 Market Trends 9.11.2 Market Forecast 10. Market Breakup by Application 10.1 Internal Analgesics 10.1.1 Market Trends 10.1.2 Market Forecast 10.2 External Analgesics 10.2.1 Market Trends 10.2.2 Market Forecast 11. Market Breakup by Region 11.1 North America 11.1.1 Market Trends 11.1.2 Market Forecast 11.2 Europe 11.2.1 Market Trends 11.2.2 Market Forecast 11.3 Asia Pacific 11.3.1 Market Trends 11.3.2 Market Forecast 11.4 Middle East and Africa 11.4.1 Market Trends 11.4.2 Market Forecast 11.5 Latin America 11.5.1 Market Trends 11.5.2 Market Forecast 12. Global Analgesics Industry: SWOT Analysis 12.1 Overview 12.2 Strengths 12.3 Weaknesses 12.4 Opportunities 12.5 Threats 13. Global Analgesics Industry: Value Chain Analysis 13.1 Overview 13.2 Research and Development 13.3 Raw Material Procurement 13.4 Manufacturing 13.5 Marketing 13.6 Distribution 13.7 End-Use 14. Global Analgesics Industry: Porters Five Forces Analysis 14.1 Overview 14.2 Bargaining Power of Buyers 14.3 Bargaining Power of Suppliers 14.4 Degree of Competition 14.5 Threat of New Entrants 14.6 Threat of Substitutes 15. Global Analgesics Industry: Price Analysis 15.1 Price Indicators 15.2 Price Structure 15.3 Margin Analysis 16. Competitive Landscape 16.1 Market Structure 16.2 Key Players 16.3 Profiles of Key Players 16.3.1 Bayer AG 16.3.2 Novartis AG 16.3.3 GlaxoSmithKline PLC 16.3.4 Pfizer Inc. 16.3.5 Johnson & Johnson 16.3.6 Reckitt Benckiser (RB) 16.3.7 Endo Pharmaceuticals 16.3.8 Bristol-Myers Squibb 16.3.9 Eli Lilly and Company 16.3.10 Sanofi |
Market Breakup by Type
- Prescription Analgesics
- OTC Analgesics
Market Breakup by Drug Class
- Opioids
- NSAID
- Others
Market Breakup by ROA
- Oral
- Parenteral
- Topical
- Transdermal
- Rectal
Market Breakup by Pain Type
- Musculoskeletal Pain
- Surgical and Trauma Pain
- Cancer Pain
- Neuropathic Pain
- Migraine
- Obstetrical Pain
- Fibromyalgia
- Pain due to Burns
- Dental/Facial Pain
- Pediatric Pain
- Others
Market Breakup by Application
- Internal Analgesics
- External Analgesics
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- Latin America
DNA SEQUENCING PRODUCTS MARKET: GLOBAL INDUSTRY TRENDS, SHARE, SIZE, GROWTH, OPPORTUNITY AND FORECAST 2019-2024
| Healthcare | Published by: IMARC GROUP | Market: |
| 140 pages | Published: 02-11-2019 |
- Healthcare
- IMARC GROUP
- 140 pages
- Published: 02-11-2019
The global DNA sequencing products market was worth around US$ 4 Billion in 2018, registering a CAGR of 15.8% during 2011-2018. The market is further projected to cross US$ 9 Billion by 2024, growing at a CAGR of 15.2% during 2019-2024. DNA sequencing is the process used for calculating the precise sequence of the four nucleotide bases within a DNA molecule, namely, cytosine, adenine, thymine and guanine. It plays an important role in mapping out the human genome as well as helps in various applied research applications. In line with this, DNA sequencing products are gaining popularity in the pharmaceutical industry as they assist researchers in understanding complex diseases and, in turn, develop personalised medicines for patients. Additionally, DNA profiling has become an integral part of forensic science as these profiles enable investigators to identify and distinguish multiple samples from a pool of DNA.
Global DNA Sequencing Products Market Drivers:
Genome mapping and sequencing of microorganisms have enabled agriculturists to use them for crops and food plants. Over the past few years, specific genes of bacteria have been used in food plants to improve their resistance against insects and pests which has increased their productivity and nutritional value. In addition to this, genomes of several domesticated livestock animals, such as chicken, pig, cow, sheep, and horse, have also been partially or completely sequenced and proven to be useful in the production of livestock with enhanced quality of meat and milk.
The role of DNA sequencing in the in-vitro diagnostics market, particularly for point-of-care diagnostics, is expected to gain momentum. DNA sequencing enables the development of precision medicine in order to offer specific treatments or therapies to patients. It also provides various platforms that enable genetic sequencing and analysis of DNA data at the point-of-care with high accuracy and rapid diagnosis.
Researchers and instrument developers have produced an array of DNA sequencing technologies which offer faster sequencing with higher accuracy at lower costs. For instance, one of the primary market players in the field, Illumina, has launched a system that consists of 10 ultra-high-throughput sequencers and can sequence about 18,000 human genomes per year.
Researchers are now using innovative technologies for genome mapping that take lesser time for completion. Other than this, the reduction in sequencing costs has led many companies to invest in R&D activities and offer cost-effective solutions such as whole genome sequencing, de novo sequencing and specific disease diagnosis.
Breakup by Product Type:
On the basis of the product type, the market has been segmented into consumables and reagents, and equipments. Currently, consumables and reagents represent the largest segment as they generate a higher return-on-investments.
Breakup by Application:
DNA sequencing products find applications across various sectors including biomarkers, diagnostics, reproductive health, personalised medicine and forensics. Amongst these, biomarkers are the most popular application segment of DNA sequencing products as they help in predicting treatment outcomes.
Breakup by End-Use:
Based on the end-use, the market has been segregated into academic and government research institutes, pharmaceutical and biotechnology companies, and hospitals and clinics. At present, DNA sequencing is majorly being used in academic and government research institutes owing to the presence of a large number of research and development projects which involve the practical implementation of data analysis and next-generation sequencing.
Regional Insights:
On a geographical front, North America accounts for the majority of the total global DNA sequencing products market. This can be accredited to the growing geriatric population, prevalence of several chronic diseases and presence of prominent drug manufacturers in the region. North America is followed by Europe, Asia Pacific, Latin America, and Middle East and Africa.
Competitive Landscape:
The nature of the market is fragmented with the presence of numerous small and large manufacturers who compete in terms of prices and quality. Some of the leading players operating in the market are:
Illumina Inc.
Thermo Fisher Scientific Inc.
Roche Diagnostics
Pacific Biosciences of California, Inc.
Beckman Coulter
Key Questions Answered in This Report:
- How has the global DNA sequencing products market performed so far and how will it perform in the coming years?
- What are the key regions in the global DNA sequencing products market?
- Which are the popular product types in the global DNA sequencing products market?
- What are the key application segments in the global DNA sequencing products market?
- What are the major end-use sectors in the global DNA sequencing products market?
- What are the various stages in the value chain of the global DNA sequencing products market?
- What are the key driving factors and challenges in the global DNA sequencing products market?
- What is the structure of the global DNA sequencing products market and who are the key players?
- What is the degree of competition in the global DNA sequencing products market?
- How are DNA sequencing products manufactured?
| 1. Preface 2. Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3. Executive Summary 4. Introduction 4.1 Overview 4.2 Key Industry Trends 5. Global DNA Sequencing Products Market 5.1 Market Overview 5.2 Market Performance 5.3 Market Breakup by Product Type 5.4 Market Breakup by Application 5.5 Market Breakup by End-User 5.6 Market Breakup by Technology 5.7 Market Breakup by Region 5.8 Market Forecast 5.9 SWOT Analysis 5.9.1 Overview 5.9.2 Strengths 5.9.3 Weaknesses 5.9.4 Opportunities 5.9.5 Threats 5.10 Value Chain Analysis 5.10.1 Research and Development 5.10.2 Raw Material Procurement 5.10.3 Manufacturing 5.10.4 Distribution 5.10.5 End-Use 5.11 Porters Five Forces Analysis 5.11.1 Overview 5.11.2 Bargaining Power of Buyers 5.11.3 Bargaining Power of Suppliers 5.11.4 Degree of Competition 5.11.5 Threat of New Entrants 5.11.6 Threat of Substitutes 6. Market Breakup by Product Type 6.1 Consumables and Reagents 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Equipments 6.2.1 Market Trends 6.2.2 Market Forecast 7. Market Breakup by Applications 7.1 Biomarkers 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Diagnostics 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Reproductive Health 7.3.1 Market Trends 7.3.2 Market Forecast 7.4 Forensics 7.4.1 Market Trends 7.4.2 Market Forecast 7.5 Personalized Medicine 7.5.1 Market Trends 7.5.2 Market Forecast 7.6 Others 7.6.1 Market Trends 7.6.2 Market Forecast 8. Market Breakup by End-User 8.1 Academic and Government Research Institutes 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Pharmaceutical and Biotechnology Companies 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Hospitals and Clinics 8.3.1 Market Trends 8.3.2 Market Forecast 8.4 Others 8.4.1 Market Trends 8.4.2 Market Forecast 9. Market Breakup by Region 9.1 North America 9.1.1 Market Trends 9.1.2 Market Forecast 9.2 Europe 9.2.1 Market Trends 9.2.2 Market Forecast 9.3 Asia Pacific 9.3.1 Market Trends 9.3.2 Market Forecast 9.4 Latin America 9.4.1 Market Trends 9.4.2 Market Forecast 9.5 Middle East and Africa 9.5.1 Market Trends 9.5.2 Market Forecast 10. Competitive Landscape 10.1 Market Structure 10.2 Market Breakup by Key Players 10.3 Profiles of Key Players 10.3.1 Illumina Inc 10.3.1.1 Company Overview 10.3.1.2 Description 10.3.1.3 Product Portfolio 10.3.1.4 Financials 10.3.1.5 SWOT Analysis 10.3.2 Thermo Fisher Scientific Inc. 10.3.2.1 Company Overview 10.3.2.2 Description 10.3.2.3 Product Portfolio 10.3.2.4 Financials 10.3.2.5 SWOT Analysis 10.3.3 Roche Diagnostics 10.3.3.1 Company Overview 10.3.3.2 Description 10.3.3.3 Product Portfolio 10.3.3.4 Financials 10.3.3.5 SWOT Analysis 10.3.4 Pacific Biosciences of California, Inc. 10.3.4.1 Company Overview 10.3.4.2 Description 10.3.4.3 Product Portfolio 10.3.4.4 Financials 10.3.4.5 SWOT Analysis 10.3.5 Beckman Coulter 10.3.5.1 Company Overview 10.3.5.2 Description 10.3.5.3 Product Portfolio 10.3.5.4 Financials 10.3.5.5 SWOT Analysis |
Market by Product Type
- Consumables and Reagents
- Equipments
Market by Applications
- Biomarkers
- Diagnostics
- Reproductive Health
- Forensics
- Personalized Medicine
- Others
Market by End-User
- Academic and Government Research Institutes
- Pharmaceutical and Biotechnology Companies
- Hospitals and Clinics
- Others
Market by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
BIOSIMILAR MARKET IN EUROPE: INDUSTRY TRENDS, SHARE, SIZE, GROWTH, OPPORTUNITY AND FORECAST 2019-2024
| Healthcare | Published by: IMARC GROUP | Market: |
| 140 pages | Published: 02-11-2019 |
- Healthcare
- IMARC GROUP
- 140 pages
- Published: 02-11-2019
The biosimilar market in Europe reached a value of US$ 2,934.6 Million in 2018. The market is further projected to reach a value of US$ 11,663.1 Million by 2024, growing at a CAGR of 24.9% during 2019-2024. The European biosimilar market represents the most mature in the world and continues to rally momentum. This market is expected to grow robustly in the next five years, as a number blockbuster biologics are scheduled to lose patent protection in Europe.
Biosimilars are biotherapeutic products which are similar to already licensed reference biologics, in terms of quality, safety and efficiency. Biosimilar manufacturers wait till the patent of the reference product expires and then seek approval from the regulatory authorities in order to produce their biosimilar versions. These manufacturers use the state-of-the-art technology for comparing the characteristics, such as purity, chemical identity and bioactivity, of the proposed biosimilar to its reference product. In 2005, a science-based regulatory framework was established in the European Union (EU) for ensuring the production of high-quality biosimilars. Later in 2006, the European Medicines Agency (EMA) approved the first biosimilar medicine, Omnitrope. Since then, a number of biosimilars belonging to various therapeutic classes have been approved in Europe.
Biosimilars Market in Europe: Drivers
Biosimilars are less expensive than their branded counterparts as they do not require extensive research and testing which saves both money and time; thereby lowering the costs. Moreover, they also have short marketing times as launching a biosimilar does not require extensive marketing as the safety and efficacy profile of their branded counterparts have already been established.
Several blockbuster biologics are expected to lose their patent protection over the next 5 to 10 years. This expiration of patents and other intellectual property rights is expected to create huge opportunities for biosimilar manufacturers.
The European population is ageing with around one fifth of the total EU population above 65 years of age. There has resulted in a significant increase in the burden of lifestyle diseases in the region. The prevalence of diseases such as diabetes, autoimmune diseases, oncology, etc. has been increasing rapidly in Europe. This is also expected to propel the market growth during the next few years.
As a result of rising healthcare costs, governments across a number of European countries have formulated policies incentivising physicians, pharmacists and patients in favour of biosimilars over branded biologics.
Market Summary:
Country-wise, the market has been segmented into Italy, Germany, United Kingdom, France, Spain and Others. In 2018, Italy represented the largest market for biosimilars in Europe.
The report has analysed the market on the basis of molecule. In 2018, Infliximab dominated the market, accounting for the highest sales. Other major molecules include Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, etc.
The report has also analysed the market on the basis of indication. Autoimmune diseases represented the biggest indication for biosimilars in 2018. Other major indications include oncology, autoimmune diseases, blood disorders, growth deficiency, diabetes, etc.
On the basis of manufacturing type, the report has segmented the market into in-house manufacturing and contract manufacturing. In 2018, in-house manufacturing accounted for a higher share.
Some of the leading players operating in the European biosimilars market include:
- Novartis
- Pfizer
- Teva
- Celltrion
- Samsung Bioepis
- Amgen
- Apotex
- Ratiopharm
- Mylan
- Merck Sharp & Dohme
- Eli Lilly
- Accord Healthcare Ltd
- Boehringer Ingelheim
- Hexal Ag
- Stada Arzneimittel Ag
This report provides a deep insight into the European biosimilars market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the European biosimilars market in any manner.
Key Questions Answered in This Report:
- How has the European biosimilars market performed so far and how will it perform in the coming years?
- What are the key regional markets in the European biosimilars industry?
- What are the major molecule types in the European biosimilars industry?
- What is the share of in-house manufacturing vs. contract manufacturing in the European biosimilars industry?
- What are the various indications in the European biosimilars industry?
- What are the price trends of biosimilars?
- What are the various stages in the value chain of the European biosimilars industry?
- What are the key driving factors and challenges in the European biosimilars industry?
- What is the structure of the European biosimilars industry and who are the key players?
- What is the degree of competition in the European biosimilars industry?
- What are the key requirements for setting up a biosimilar manufacturing plant?
- How are biosimilars manufactured?
- What are the machinery requirements for setting up a biosimilar manufacturing plant?
- What is the capital cost for setting up a biosimilar manufacturing plant?
| 1. Preface 2. Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3. Executive Summary 4. Europe Biosimilars Market – Introduction 4.1 Overview 4.2 WHO and EMA Terminology on Biosimilars 4.3 Biosimilars and Generics 4.4 Biosimilars and Branded Biological Products 5. Europe Biosimilars Market 5.1 Market Overview 5.2 Historical and Current Market Trends 5.3 Market Breakup by Country 5.4 Market Breakup by Molecule 5.5 Market Breakup by Indication 5.6 Market Breakup by Manufacturing Type 5.7 Patent Landscape 5.8 Market Forecast 6. Market Breakup by Country 6.1 Italy 6.1.1 Market Performance 6.1.2 Key Players and Biosimilars 6.1.3 Market Forecast 6.2 Germany 6.2.1 Market Performance 6.2.2 Key Players and Biosimilars 6.2.3 Market Forecast 6.3 France 6.3.1 Market Performance 6.3.2 Key Players and Biosimilars 6.3.3 Market Forecast 6.4 United Kingdom 6.4.1 Market Performance 6.4.2 Key Players and Biosimilars 6.4.3 Market Forecast 6.5 Spain 6.5.1 Market Performance 6.5.2 Key Players and Biosimilars 6.5.3 Market Forecast 6.6 Rest of Europe 6.6.1 Market Performance 6.6.2 Market Forecast 7. Market Breakup by Molecule 7.1 Infliximab 7.2 Insulin Glargine 7.3 Epoetin Alfa 7.4 Etanercept 7.5 Filgrastim 7.6 Somatropin 7.7 Rituximab 7.8 Follitropin Alfa 8. Market Breakup by Manufacturing Type 8.1 In-house Manufacturing 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Contract Manufacturing 8.2.1 Market Trends 8.2.2 Market Forecast 9. Market Breakup by Indication 9.1 Auto-Immune Diseases 9.2 Blood Disorder 9.3 Diabetes 9.4 Oncology 9.5 Growth Deficiency 9.6 Female Infertility 10. European Biosimilar Market: SWOT Analysis 10.1 Overview 10.2 Strengths 10.3 Weaknesses 10.4 Opportunities 10.5 Threats 11. European Biosimilar Market: Value Chain Analysis 11.1 Characterizing the Existing Innovator Drug 11.2 Research and Development 11.2.1 Characterization of Biosimilars 11.2.2 Developing a Unique Cell Line 11.3 Product Development 11.3.1 Pre-Testing 11.3.2 Intermediary Clinical Testing (PK/PD) 11.3.3 Confirmatory Clinical Phase-III 11.4 Final Product Formulation 11.5 Marketing and Distribution 12. Porter’s Five Forces Analysis 12.1 Overview 12.2 Bargaining Power of Buyers 12.3 Bargaining Power of Suppliers 12.4 Degree of Competition 12.5 Threat of New Entrants 12.6 Threat of Substitutes 13. Price Analysis 13.1 Key Price Indicators 13.2 Price Trends 14. Requirements for Setting Up a Generic Drug Manufacturing Plant 14.1 Manufacturing Process 14.2 Raw Material Requirements 14.3 Raw Material Pictures 14.4 Land and Construction Requirements 14.5 Machinery and Infrastructure Requirements 14.6 Machinery Pictures 14.7 Plant Layout 14.8 Packaging Requirements 14.9 Utility Requirements 14.10 Manpower Requirements 15. Competitive Landscape 15.1 Market Structure 15.2 Key Players 15.3 Profiles of Key Players 15.3.1 Novartis 15.3.2 Pfizer 15.3.3 Teva 15.3.4 Celltrion 15.3.5 Merck Sharp & Dohme 15.3.6 Samsung Bioepis 15.3.7 Eli Lilly 15.3.8 Accord Healthcare Ltd. 15.3.9 Amgen 15.3.10 Boehringer Ingelheim 15.3.11 Hexal Ag 15.3.12 Apotex 15.3.13 Stada Arzneimittel Ag 15.3.14 Ratiopharm 15.3.15 Mylan |
Market by Country
- Italy
- Germany
- France
- United Kingdom
- Spain
- Rest of Europe
Market by Molecule
- Infliximab
- Insulin Glargine
- Epoetin Alfa
- Etanercept
- Filgrastim
- Somatropin
- Rituximab
- Follitropin Alfa
Market by Manufacturing Type
- In-house Manufacturing
- Contract Manufacturing
Market by Indication
- Auto-Immune Diseases
- Blood Disorder
- Diabetes
- Oncology
- Growth Deficiency
- Female Infertility
Buy Chapters or Sections
Why choose us
-
24/5 Research supportGet your queries resolved from an industry expert.
-
Custom research serviceDesign an exclusive study to serve your research needs.
-
Quality assuranceA testimonial for service in the form of BBB “A” Accreditation.
-
Information securityYour personal and confidential information is safe and secure.
Duchenne Muscular Dystrophy Treatment Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 115 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 115 pages
- Published: 07-06-2019
Market Overview
The propelling factors for the growth of the Duchenne muscular dystrophy (DMD) treatment market include the rising disease burden of Duchenne muscular dystrophy, increasing investments in biopharmaceutical R&D to release novel disease therapies, and increasing awareness campaigns for DMD.
Currently, there is an increase in the number of clinical trials for testing the future treatment for Duchenne muscular dystrophy. The only accepted pharmacological therapy for the treatment of DMD is corticosteroid-based anti-inflammatory treatment.
The rising prevalence of chronic diseases, such as cardiovascular and neurovascular diseases, and arthritis, and increasing healthcare insurance coverage are the major factors likely to accelerate the growth of the market. The pharmaceutical drug discovery and development have also grown rapidly in the past few years. As there have been great breakthroughs in technology in the last few years that may facilitate research processes and as the explosion of science in understanding the causes of diseases has made target selection more rational than ever, almost all major companies are now concentrating on R&D, which is likely to have a major impact on the market in the coming years.
Furthermore, with increasing awareness among people and with the government’s urgency for the treatment of the disease, there is a big opportunity for the companies to conduct their trails and for new drugs launches, due to which, the market is expected to grow in the coming years.
Scope of the Report
As per the scope of the report, Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. It is a rare muscle disease, which majorly affects males. There are novel drugs and therapies, disease-modifying, and mutation-specific therapies that are some of the emerging major breakthroughs in the DMD treatment market.
Key Market Trends
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Segment is Expected to Grow Fastest During the Forecast Period
Corticosteroids are the only known pharmacological treatment for DMD and help to suppress muscle inflammation. This treatment is being limited by its inadequate therapeutic efficacy, and considerable side effects, and hence, non-steroidal anti-inflammatory drugs (NSAIDs) can be used to reduce the inflammation of muscles. The nonsteroidal anti-inflammatory drugs are expected to witness a CAGR of 49.2% over the forecast period.
However, other therapies and treatments include stem cell therapy, repurposing drugs, anti-fibrotics, myostatin inhibition, gene editing (CRISPR/Cas9), etc. Currently, prednisone/prednisolone and deflazacort have been used for the treatment of Duchenne muscular dystrophy, which is expected to drive the growth of the market, over the forecast period.
North American Region holds the Largest Market Share of the Market Currently and is Believed to Follow the Same Trend Over the Forecast Period
North America dominates the global Duchenne muscular dystrophy market, due to new product innovations, high healthcare expenditure, and government awareness programs. The United States has dominated the regional market and is projected to maintain its lead, owing to the rising disease incidence and anticipated launch of promising pipeline candidates. In addition, the market is expected to grow with the increasing clinical trials around the world, especially in the United States and Europe.
Competitive Landscape
With increasing campaigns and awareness programs, the number of patients is expected to come down, and hence, many companies are conducting campaign programs that help to improve focus on medicines for DMD treatment. There are also very few companies for new drug research for rare diseases because it needs bigger funds. Therefore, the market is not well established in many other therapeutic areas. However, it is expected to experience high growth and expand during the forecast period.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Disease Burden of Duchenne Muscular Dystrophy (DMD)
4.2.2 Increasing Investments in Biopharmaceutical R&D to Release Novel Disease Therapies
4.2.3 Increasing Awareness Campaigns for DMD
4.3 Market Restraints
4.3.1 Lack of Standardization to Measure Clinical Efficacy Across All Stages of DMD
4.3.2 Stringent Regulatory Framework with High Product Cost Burden
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 By Therapeutic Approach and Treatment Type
5.1.1 Molecular-based Therapies
5.1.1.1 Mutation Suppression
5.1.1.2 Exon Skipping
5.1.2 Steroid Therapy
5.1.2.1 Corticosteroids
5.1.3 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
5.1.4 Other Therapeutic Approaches and Treatment Types
5.2 By End User
5.2.1 Hospitals/Clinics
5.2.2 Ambulatory Centers
5.2.3 Other End Users
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. Competitive Landscape
6.1 Company Profiles
6.1.1 BioMarin
6.1.2 Bristol-Myers Squibb Company
6.1.3 Fibrogen Inc.
6.1.4 Eli Lilly and Company
6.1.5 Nobelpharma Co. Ltd
6.1.6 NS Pharma Inc.
6.1.7 Pfizer Inc.
6.1.8 PTC Therapeutics
6.1.9 Santhera Pharmaceuticals
6.1.10 Sarepta Therapeutics
7. Market Opportunities and Future Trends
By Therapeutic Approach and Treatment Type
Molecular-based Therapies
Mutation Suppression
Exon Skipping
Steroid Therapy
Corticosteroids
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Other Therapeutic Approaches and Treatment Types
By End User
Hospitals/Clinics
Ambulatory Centers
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Mexico General Surgical Devices Market – Growth, Trends, and Forecasts (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 74 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 74 pages
- Published: 07-06-2019
Market Overview
The Mexican general surgical devices market is expected to record a CAGR of around 4.8% over the forecast period, 2019-2024. Certain factors that are accelerating the growth of the market include rising demand for minimally invasive devices, technological advancements in general surgical devices, and rising unmet healthcare needs in the country, along with the rising expenditure on health.
This rise in healthcare expenditure is anticipated to accelerate medical infrastructural development, which is likely to fuel the growth of the surgical devices market in Mexico. Major manufacturers of surgical devices are focusing on gaining a foothold in emerging economies, such as Brazil and Mexico, in order to expand their business operations and explore new markets, thus creating an advanced healthcare infrastructure. Thus, increasing healthcare expenditure, strong local manufacturing base, and rapidly developing healthcare infrastructure, have led to increased and advanced surgical procedures performed in this country. Hence, these factors are likely to offer immense growth opportunities in the Mexican surgical procedures market.
Scope of the Report
The general surgical devices are specially designed tools or instruments that serve a specific purpose during a surgery, which include scissors, forceps, surgical needles, etc.
Key Market Trends
Handheld Devices Segment by Product is Expected to Record the Highest CAGR over the Forecast Period
The handheld devices segment of the Mexican general surgical devices market is expected to register the highest CAGR over the forecast period.
The demand for surgical equipment is increasing in response to the rising need for minimally invasive surgeries in the country. Handheld surgical devices are becoming increasingly advanced. The large-scale use of advanced surgical instruments in recent years is driving the handheld devices segment in Mexico. The development of advanced tools, like robotic hand-held surgical devices for laparoscopic interventions, enhances a surgeon’s ability. Many innovations have been made owing to the need for high reliability, accuracy, and patient safety. Therefore, there is an increasing demand for handheld devices, which in turn, is helping the segment to grow faster.
Competitive Landscape
Some of the major companies in the Mexican general surgical devices market are B. Braun Melsungen AG, Boston Scientific Corporation, Conmed Corporation, Medtronic PLC, and Stryker Corporation. Along with these big players, the market is also witnessing some of the smaller players that hold a substantial market share.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Demand for Minimally Invasive Devices
4.2.2 Technological Advancements in General Surgical Devices
4.2.3 Rising Unmet Healthcare Needs
4.2.4 Rising Health Expenditure
4.3 Market Restraints
4.3.1 High Capital Expenses Needed to Produce Surgical Equipment
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 By Product
5.1.1 Handheld Devices
5.1.2 Laproscopic Devices
5.1.3 Electro Surgical Devices
5.1.4 Wound Closure Devices
5.1.5 Trocars and Access Devices
5.1.6 Other Products
5.2 By Application
5.2.1 Gynecology and Urology
5.2.2 Cardiology
5.2.3 Orthopaedic
5.2.4 Neurology
5.2.5 Other Applications
6. Competitive Landscape
6.1 Company Profiles
6.1.1 B. Braun Melsungen AG
6.1.2 Boston Scientific Corporation
6.1.3 Conmed Corporation
6.1.4 Integer Holdings Corporation
6.1.5 Johnson & Johnson
6.1.6 Medtronic PLC
6.1.7 Stryker Corporation
7. Market Opportunities and Future Trends
By Product
Handheld Devices
Laproscopic Devices
Electro Surgical Devices
Wound Closure Devices
Trocars and Access Devices
Other Products
By Application
Gynecology and Urology
Cardiology
Orthopaedic
Neurology
Other Applications
Drug Discovery Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 115 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 115 pages
- Published: 07-06-2019
Market Overview
The propelling factors for the growth of the drug discovery market include the rising prevalence of a wide range of diseases (such as cardiovascular and CNS-related disorders), rising healthcare expenditure, and upcoming patent expiration of blockbuster drugs.
The diverse range of diseases, primarily cardiovascular disease, infectious diseases, diabetes, and kidney-related complications, has a high prevalence, globally. Thus, the increasing prevalence of a diverse range of diseases among all age groups and its burden, globally, drives the demand for drug discovery and its market.
There has been an upsurge in the usage of advanced technologies, such as high throughput, bioinformatics and combinatorial chemistry for better drug candidate identification. Drug discovery has evolved significantly with emerging technologies, helping the process to become more refined, accurate, and less time consuming. Due to automation, multi-detector readers, imaging hardware and software, high-throughput screening is one of the most widely used drug discovery technologies.
In recent years, there has been a rising demand for specialty medicines that is expected to ultimately influence the small molecule drug discovery market in a positive manner, as most of the specialty medicines are small molecules.
The gradual rise in the healthcare expenditure regionally helps the new pharmaceutical technology advancement. Although with high expenditure, there is a need for redirecting the resources, the transition toward better usability of healthcare expenditure for drug development is under progress.
Scope of the Report
As per the scope of the report, drug discovery is a process, which aims at identifying a compound therapeutically useful in treating and curing diseases. Typically, a drug discovery effort addresses a biological target that has been shown to play a role in the development of the disease or starts from a molecule with interesting biological activities. In the recent past, drug discovery has evolved significantly with emerging technologies, helping the process to become more refined, accurate, and less time consuming.
Key Market Trends
Biologics Drug is the Segment that is Expected to Grow Fastest under Drug Type
A biologic drug is a product that is produced from living organisms or contains components of living organisms. Biologic drugs include a wide variety of products derived from human, animal, or microorganisms. Biologic drugs are used for the treatment of numerous diseases and conditions and are the most advanced therapies available. Biologic treatments are for autoimmune diseases, which include the treatments for rheumatoid arthritis, psoriasis, ulcerative colitis, Crohn’s disease, and a range of related disorders, and have continued to see increasing usage across geographies. The biologic drugs are expected to be fueled by innovations in oncology, autoimmune, and diabetes treatments, with particular important opportunities for biologics in the oncology and autoimmune sectors.
The increasing applications of small molecule drugs for the treatment of chronic diseases are leading to the increased demand for these drugs in the market. Moreover, due to the aforementioned factors, small molecule drugs dominate the biologics in the current healthcare market.
Asia-Pacific Holds the Fastest Growth and is Expected to Follow the Same Trend Over the Forecast Period
The Asia Pacific is the fastest-growing region, due to the presence of skilled labor at an affordable cost, the rise in disposable income, and favorable government policies that are contributing to the market growth. There has also been phenomenal growth in the outsourcing companies in the Chinese region, over the last decade, which has complemented the restructuring of the R&D that has taken place. Thus, owing to the large deals of pharmaceutical companies and more number of research being done, the market for drug discovery is expected to grow.
Competitive Landscape
The market studied has various pharmaceutical companies that are investing billions of dollars in artificial intelligence (AI), in order to make the drug discovery process significantly faster and cost efficient. The pharmaceutical and biotech companies are increasing their collaborations with contract development and manufacturing organizations; thus, playing a crucial role in the development and innovation of new drugs.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of a Diverse Range of Diseases
4.2.2 Technological Advancements and Innovations
4.2.3 Increasing Healthcare Expenditure
4.2.4 Patent Expiration of Blockbuster Drugs
4.3 Market Restraints
4.3.1 Huge Capital Investment with Low-profit Margins
4.3.2 Stringent Government Regulations
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 By Drug Type
5.1.1 Small Molecule Drug
5.1.2 Biologic Drug
5.2 By Technology
5.2.1 High Throughput Screening
5.2.2 Biochips
5.2.3 Bioinformatics
5.2.4 Pharmacogenomics and Pharmacogenetics
5.2.5 Combinatorial Chemistry
5.2.6 Nanotechnology
5.2.7 Spectroscopy
5.2.8 Metabolomics
5.2.9 Other Technologies
5.3 By Service
5.3.1 Drug Metabolism and Pharmacokinetics (DMPK) Services
5.3.2 Pharmaceutical Services
5.3.3 Chemical Services
5.3.4 Biological Services
5.4 By End User
5.4.1 Research Institutes
5.4.2 Pharmaceutical Companies
5.4.3 Contract Research Organizations(CROs)
5.4.4 Other End Users
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 United Kingdom
5.5.2.2 Germany
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East & Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6. Competitive Landscape
6.1 Company Profiles
6.1.1 Pfizer Inc.
6.1.2 GlaxoSmithKline PLC
6.1.3 Merck & Co. Inc.
6.1.4 Agilent Technologies Inc.
6.1.5 Eli Lilly and Company
6.1.6 F. Hoffmann-La Roche Ltd
6.1.7 Bayer AG
6.1.8 Abbott
6.1.9 AstraZeneca PLC
6.1.10 Shimadzu Corp.
7. Market Opportunities and Future Trends
By Drug Type
- Small Molecule Drug
Biologic Drug
By Technology
High Throughput Screening
Biochips
Bioinformatics
Pharmacogenomics and Pharmacogenetics
Combinatorial Chemistry
Nanotechnology
Spectroscopy
Metabolomics
Other Technologies
By Service
Drug Metabolism and Pharmacokinetics (DMPK) Services
Pharmaceutical Services
Chemical Services
Biological Services
By End User
Research Institutes
Pharmaceutical Companies
Contract Research Organizations(CROs)
Other End Users - Geography
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America